Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by Gamestorm7on Nov 01, 2018 1:24pm
124 Views
Post# 28909111

Keep Holding That Breath

Keep Holding That BreathMany investors in iCo are under water.  I believe someone previously indicated that when the company's share float traded over 2 - 3 times, the average share cost was in that $0.15 - $0.16 range.  I myself am holding a loss near 50%.  I will not be selling anytime soon.  There are too many indications that there is more positive than negative coming to this company.  If you look at the time line of events, 5 months from the inital breakout and spike to where we are at now isn't that long.  The company is addressing the funding issue for continued operations as mentioned in the last NR.  In my mind, this is addressed and we will find out a resolution this quarter.  Other people have indicated no news until March or whatever; however, I believe we get news regarding this before the new year.  Anyway, I am going to continue to hold my breath and hope fellow investors like myself can as well.  Patience will pay off on this play, I truly believe that.  My opinions only.  GLTA
<< Previous
Bullboard Posts
Next >>